In this post we summarize its usefulness, the advantages and disadvantages, and we present two examples.

There are many guidelines that teach you how to do an MCDA. Based on the guidelines available, and on the learnings we have been accumulating, here are the 10 steps...

Multi Criteria Decision Analysis (MCDA) is a tool to support decision making in health care. It complements other tools. It does not replace them. The more complex the decisions, the...

On May 23rd , we joined the learning event about the BeNeLuxA initiative. https://www.healixia.be/meetings-detail-pagina/611/healixia-conference-deep-dive-into-beneluxa  More about the BeNeLuxA initiative: https://beneluxa.org/collaboration

On 6 April 2023 at WTC Rotterdam, Vivactis HM3A attended the 10th edition of the leading conference for key players in Health & Life Sciences, Innovation for Health! The theme for this edition was Digital...

Vivactis Group, the leading European healthcare consultancy group, announces its acquisition of Weber, a Market Access Consultancy firm and specialist in Health Economics and Outcomes Research (HEOR). The acquisition strengthens...

Vivactis HM3A attended the the European Health Summit on December 8th in Brussels, Belgium.

The health app regulatory framework for financing of medical apps was announced in January 2021. This framework consists of a so-called ‘validation pyramid’ with 3 levels. Apps at level 3...

How and when will it impact your business?

Vivactis HM3A attended the the Engage networking event on November 24th in Brussels, Belgium. The event was organised by Pharma.be

Vivactis HM3A attended the the Value Based Healthcare event on November 22nd in Brussels, Belgium. The event was organised by beMedTech with as topic 'Geïntegreerde zorg: TO .be OR NOT...

Vivactis HM3A attended the Science for Health event on November 21st in Brussels, Belgium. The event was organised by MEDVIA with as topic 'Advancing Gene Therapy'.

We are currently looking for a Market Access Consultant for the BeNeLux team to sustain our growth.

What are Health Technology Assessments? What is their purpose? Why does the new regulation matter?